Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 22

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1
Chunk 22
---
 II), award amount $1,484,350, dates September 19, 2016 through September 16, 2021. Subcontract to Georgetown
    University. Intellectual property consists of cell cultures and is property of Shuttle Pharmaceuticals, Inc. via licensing agreement.

    ●
    SBIR
    contracts #HHSN261201600027C ($299,502) and #75N81018C00031: Predictive Biomarkers of Prostate Cancer Patient Sensitivity for Radiation
    Late Effects, award amount $1,903,015, dates September 16, 2019 through March 15, 2022. Subcontract to Georgetown University. Intellectual
    property is owned by subcontractor Georgetown University with option to license to Shuttle Pharmaceuticals, Inc.

Prostate
Cancer Studies to Address Health Disparities

Prostate
cancer health disparities studies have shown that African American men are at higher risk for developing prostate cancer, as well as
at higher risk of cancer specific death rates as compared to Caucasian American men. The causes of disparities have been attributed to
socioeconomic differences, environmental exposures and biological factors. Most disparities studies have been population based, in part,
due to the lack of relevant in vitro and in vivo models to support biological studies.

Shuttle
Pharma has been awarded Phase I and II SBIR contracts entitled “Cell-based models for prostate cancer health disparity research”
to develop African American prostate cancer cell lines with donor matched normal prostate epithelial cell lines from African American
men.

The
commercialization of the prostate cells will require additional support through the SBIR funding mechanism. Companies that have completed
Phase I and II SBIR awards are eligible to apply for Phase IIb SBIR funding. These awards were historically intended to de-risk a project
by providing matching funding for product development to commercialization. We intend to apply for such government funding to advance
laboratory facilities and to expand the availability of the cell cultures. We did not raise capital through our IPO for the health disparities
project. Should we not be successful with SBIR IIb funding, we will pause and may have to terminate this project.

Prostate
Cancer Biomarker Development

Patients
treated for prostate cancer may experience treatment related late effects that adversely affect quality of life and may prove life-threatening.
Shuttle Pharma has been awarded a Phase I SBIR contract entitled “Predictive biomarkers for prostate cancer patient sensitivity
for radiation late effects” to determine the technical and commercial feasibility of a